[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 50.16.52.237. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 458
Citations 0
Observation
February 2016

Sorafenib-Induced Eruption Mimicking Erythema Multiforme

Author Affiliations
  • 1Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
  • 2Department of Dermatology, Duke University Medical Center, Durham, North Carolina
  • 3Department of Dermatology, University of Pennsylvania, Philadelphia
  • 4Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
JAMA Dermatol. 2016;152(2):227-228. doi:10.1001/jamadermatol.2015.2930

Sorafenib tosylate is an orally administered small-molecule multikinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR)-2 and -3, platelet-derived growth factor receptor (PDGFR), rearranged during transfection (RET), FMS-like tyrosine kinase 3 (FLT3), c-KIT, and C- and B-Raf. This drug is approved by the US Food and Drug Administration for the treatment of advanced renal cell carcinoma, unresectable hepatocellular carcinoma, and radioactive iodine–resistant, advanced, differentiated thyroid carcinoma. Cutaneous adverse effects of this drug affect up to 91% of patients.1 Commonly reported eruptions include nonspecific rash and hand-foot skin reactions, which can be dose-limiting toxic reactions. Erythema multiforme (EM) has also been described.26

First Page Preview View Large
First page PDF preview
First page PDF preview
×